<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mechanisms and clinical implications of glucocorticoid resistance in asthma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mechanisms and clinical implications of glucocorticoid resistance in asthma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mechanisms and clinical implications of glucocorticoid resistance in asthma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ian M Adcock, FSB</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce S Bochner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Glucocorticoids (GCs) have potent antiinflammatory actions and are the most effective anti-inflammatory agents in the treatment of asthma. It is evident that asthma is a syndrome with many distinct and overlapping phenotypes with severe GC-refractory asthma at one end of a spectrum of GC responsiveness [<a href="#rid1">1</a>]. Patients with GC-refractory asthma account for a large percentage of the overall costs for asthma worldwide, but also provide unique insights into the mechanisms of GC action. These patients should not be confused with those who either do not take their anti-inflammatory medication or do not have access to the correct treatments [<a href="#rid2">2,3</a>]. </p><p>The European Respiratory Society/American Thoracic Society (ERS/ATS) and the Global Initiative for Asthma (GINA) guidelines provide pragmatic approaches to treatment strategy for severe asthma based on patient stratification and expert opinion [<a href="#rid3">3,4</a>].</p><p>The basic mechanisms of glucocorticoid resistance in asthma and clinical implications for diagnosis and management of severe asthma will be reviewed here. GC use in GC-sensitive asthma and GC resistance in other disease states are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Glucocorticoid (GC) responsiveness represents a continuous spectrum, with GC-resistant individuals falling at one end of a unimodal distribution. Patients with severe asthma who are poorly responsive to high doses of GCs and are <strong>without confounding factors </strong> (<a class="graphic graphic_table graphicRef61331" href="/z/d/graphic/61331.html" rel="external">table 1</a>) have been termed GC-resistant [<a href="#rid4">4</a>]. A larger subset of patients with asthma that is poorly-controlled despite optimal treatment or who experience worsening of asthma control during GC withdrawal have severe asthma and are considered relatively GC-insensitive [<a href="#rid4">4</a>]. High doses of GCs usually indicate a daily dose of 1000 mcg or more of inhaled <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> propionate or 2000 mcg or more of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a>, the equivalent  (<a class="graphic graphic_table graphicRef68983" href="/z/d/graphic/68983.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3"><span class="h1">MECHANISMS OF GLUCOCORTICOID ACTION</span><span class="headingEndMark"> — </span>GCs exert their major effects by influencing target cell transcriptional regulation and protein synthesis  (<a class="graphic graphic_figure graphicRef67246" href="/z/d/graphic/67246.html" rel="external">figure 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Upon entering the cell, GCs bind to a cytoplasmic glucocorticoid receptor (GR or NR3C1), which is a member of the nuclear receptor superfamily, to form a GC-GR complex.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GR is expressed in all cells in the airway to a varying extent [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GR can exist in several isoforms including GRalpha, the major form, as well as GRbeta which acts as a dominant negative isoform of GRalpha [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The GC-GR complex then undergoes a conformational change revealing a nuclear localization signal and translocates into the nucleus. Within the nucleus, the activated GR binds to cis-acting DNA sequences (glucocorticoid-response elements [GREs]) and generally upregulates the transcription of specific target genes  (<a class="graphic graphic_figure graphicRef67246" href="/z/d/graphic/67246.html" rel="external">figure 1</a>) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Binding of the activated GR-ligand complex to DNA can also occur at a negative glucocorticoid-response element (nGRE). These sequences are implicated in the control of over 1000 genes in man and can result in repression of transcription [<a href="#rid7">7</a>]. The induction or repression of target genes ultimately results in the altered expression of GC-regulated proteins, such as increased transcription of antiinflammatory genes such as the cytokine interleukin (IL)-10 [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GC-induced gene transcription is associated with changes in chromatin structure as evidenced by enhanced acetylation of core histones around which DNA is wound. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of glucocorticoids, systemically or through inhalation, results in a significant increase in systemic or local IL-10 synthesis, respectively. In vitro studies have shown a concentration-dependent induction of T lymphocyte IL-10 expression by glucocorticoids [<a href="#rid8">8</a>]. IL-10 inhibits proinflammatory cytokine production, antigen presentation, T cell activation, and also mast cell and eosinophil function [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The glucocorticoid receptor-ligand complex can also modulate transcription of genes in a hormone-dependent manner through tethering to other DNA-bound transcription factors eg, cyclic adenosine monophosphate (AMP) response element binding protein (CREB), activation protein (AP)-1, nuclear factor kappa B (NF-kappaB), and signal transducers and activators of transcription (STATs) [<a href="#rid6">6,9</a>], rather than by direct binding to GREs. Activity of these other transcription factors is largely regulated by extracellular signals received by cell surface receptors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activated GRs (ie, the GC-GR complex) can recruit histone deacetylase (HDAC) complexes to sites of NF-kappaB-driven proinflammatory gene transcription and thereby decrease inflammatory gene transcription [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ability of activated GRs to associate with DNA and co-repressor/activator proteins is regulated by its phosphorylation status [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>These molecular actions of GCs are sufficient in most asthmatics to repress airway inflammation, reduce airway hyperresponsiveness and improve lung function. However, they are not a cure for asthma as symptoms return following withdrawal.</p><p></p><p class="headingAnchor" id="H4"><span class="h1">MECHANISMS OF GLUCOCORTICOID RESISTANCE</span><span class="headingEndMark"> — </span>Glucocorticoid (GC) resistance is probably produced by the summative effect of a number of heterogeneous mechanisms  (<a class="graphic graphic_figure graphicRef88276" href="/z/d/graphic/88276.html" rel="external">figure 2</a>). As the preceding section implies, modulation of GC activity theoretically could occur through changes in binding kinetics of the cytosolic or nuclear receptors, or through alterations in the interactions with other transcription factors. Defects in most aspects of intracellular glucocorticoid receptor (GR) activity, such as GR expression levels, binding of GCs to GR and nuclear translocation of GC-GR complex, have been implicated as being defective in patients with severe asthma. However, is it likely that the major mechanisms for GC resistance occur distal to the nuclear translocation step, such as in splicing of RNA, cytokine expression, binding to GC response elements on DNA, and interactions of the GC-GR complex with other nucleoproteins. Thus far, GC resistance in asthma <strong>cannot</strong> be explained by malabsorption or pharmacokinetic mechanisms. </p><p class="headingAnchor" id="H913131512"><span class="h2">Genetic determinants</span><span class="headingEndMark"> — </span>There are few data addressing whether GC insensitivity is genetically determined although genome-wide association studies indicate other genetic links to severe asthma (eg, ORMDL3, GSDMB, interleukin [IL]-1RL1) [<a href="#rid12">12</a>]. Given the marked variability in the dose of glucocorticoids needed to inhibit T-cell proliferative responses in normal individuals, it is possible that there are genetic determinants of glucocorticoid responsiveness that only become manifest clinically with the development of a disease process requiring GC therapy. A functional polymorphism in glucocorticoid-induced transcript 1 (GLCCI1) has been linked to extremes of GC responsiveness in a genome wide study [<a href="#rid13">13</a>]. Additionally, there may be differences between racial groups as a GR D641V variant is associated with GC-resistant asthma in the Chinese Han population [<a href="#rid14">14</a>]. Finally, the 3-beta-hydroxysteroid dehydronease-1 (HSD3B1; 1245) allele regulates the adrenal production of potent androgens and is associated with GC resistance in the Severe Asthma Research Program (SARP) cohort [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Altered splicing of GC receptor premessenger RNA</span><span class="headingEndMark"> — </span>Alternative splicing of GR RNA can produce C-terminal isoforms termed GC receptor-alpha (GRalpha) and GC receptor-beta (GRbeta) along with several N-terminal truncated isoforms of both GRalpha and GRbeta [<a href="#rid16">16</a>]. These isoforms may contribute to GC-resistance in severe asthma by attenuating the ability of GRalpha to translocate to the nucleus and modulate gene expression. However, conflicting data exist. The expression of GRbeta is significantly increased in some patients with GC-resistant asthma and may contribute to GC resistance [<a href="#rid17">17,18</a>]. Autopsies of patients who suffered fatal asthma have revealed increased expression of GRbeta, although it is uncertain if this is due to GC treatment or if GRbeta causes severe asthma [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes"</a>.)</p><p>GRbeta expression is enhanced by bacterial superantigens [<a href="#rid20">20</a>] which may account for the relative GC refractory nature of asthma exacerbations. This refractoriness is also seen in viral-induced exacerbations [<a href="#rid21">21,22</a>] where the mechanism may involve inhibition of GR DNA binding [<a href="#rid23">23</a>]. </p><p class="headingAnchor" id="H6"><span class="h2">Altered cytokine expression</span><span class="headingEndMark"> — </span>Peripheral blood mononuclear cells (PBMCs), particularly the CD4+ T lymphocytes and monocytes, and airway structural cells exhibit a defective GC response in GC-resistant asthma. Airway cells from patients with GC-sensitive compared with GC-resistant asthma have different patterns of cytokine gene expression and distinct responses to GC therapy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL-2 and IL-4</strong> – Alterations in the cytokine milieu may strongly influence responsiveness to GCs. For example, the number of bronchoalveolar lavage (BAL) cells expressing IL-2 and IL-4 messenger RNA was greater in GC-resistant asthmatics compared to GC-sensitive patients [<a href="#rid24">24</a>]. PBMCs collected from normal subjects exposed to a combination of recombinant IL-2 and IL-4 demonstrate dose-dependent GC resistance [<a href="#rid25">25</a>]. </p><p></p><p class="bulletIndent1">IL-2 and IL-4 activate a specific kinase (p38 mitogen activated protein kinase [MAPK]) whose expression is enhanced in GC-resistant asthma. Inhibitors of p38 MAPK are able to restore GC sensitivity in peripheral blood cells, BAL macrophages, and airway smooth muscle cells from patients with severe asthma [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL-10</strong> – Synthesis of IL-10 is deficient in the airways of asthmatics as compared with controls, and polymorphisms of the IL-10 gene, leading to impaired expression of IL-10, are associated with a more severe disease phenotype [<a href="#rid28">28</a>]. CD4+ T lymphocytes from GC-resistant asthmatics have a marked deficiency in the capacity to synthesize IL-10 following in vitro stimulation in the presence of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> with IL-10 levels being restored by vitamin D3 treatment of cells from both adults and children [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional T-cell and cytokine profiles in glucocorticoid-resistant asthma</strong> – Several additional subsets of patients with GC-refractory asthma have been characterized based on cytokine or T-cell responses. One of these subsets is notable for elevated levels of Th17 cytokines, such as IL-17 [<a href="#rid31">31,32</a>], which are not reduced by glucocorticoids and can drive glucocorticoid insensitivity in animals and human airway epithelial cells [<a href="#rid33">33</a>]. Vitamin D3, however, is able to attenuate IL-17 production in cell culture models, reducing inflammation and enhancing steroid sensitivity [<a href="#rid34">34</a>]. The clinical implications of these findings have not been determined.</p><p></p><p class="bulletIndent1">Another novel glucocorticoid-insensitive cytokine, IL-33, has also been implicated in airway remodeling in children with severe treatment refractory asthma [<a href="#rid35">35</a>]. One clinical trial of an IL-33 inhibitor and basic research into IL-33 activation pathways suggest particular utility of targeting this pathway in patients with severe GC-resistant non-T2 asthma [<a href="#rid36">36-39</a>].</p><p></p><p class="bulletIndent1">Another commonly seen cytokine pattern is heightened interferon gamma activity. Reduced Th2 and IL-17 responses and enhanced interferon (IFN)-gamma expression were reported in the BAL of individuals with GC-resistant asthma [<a href="#rid40">40</a>] as well as increased expression of IFN-stimulated genes (ISG) in epithelial brushings [<a href="#rid41">41</a>]. The effects of IFN-gamma-related activation on airway hyperresponsiveness are modulated by CCR5 [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1">In one cohort, elevated plasma IL-6 levels were associated with worse lung function and more frequent exacerbations in both obese and nonobese subjects [<a href="#rid43">43</a>]. Activation of IL-6 on epithelial cells via trans-signaling leads to a transcriptional program associated with frequent exacerbations, blood eosinophilia, and submucosal infiltration of T cells and macrophages in the absence of type 2 inflammation [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">Finally, reduced numbers of BAL Treg and mucosal associated invariant T (MAIT) cells are found in severe asthma [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines", section on 'Cytokine profiles and functions of CD4+ T helper cell subsets'</a>.)</p><p></p><p class="bulletIndent1">These and other studies highlight the importance of defining the airway compartment being studied in severe asthma. Single cell RNA-sequencing analysis of immune cells in BAL and/or biopsies from these patients will provide better insight into the contribution of these pathways and T-cell subtypes to GC-insensitive asthma.</p><p></p><p class="headingAnchor" id="H7"><span class="h2">GR binding to GC response elements</span><span class="headingEndMark"> — </span>Early studies indicated that the activated GR in peripheral blood cells of GC-insensitive asthmatics were less able to bind to DNA than cells from patients with GC-sensitive asthma and non-atopic control subjects  (<a class="graphic graphic_figure graphicRef75439" href="/z/d/graphic/75439.html" rel="external">figure 3</a>) [<a href="#rid46">46</a>]. It is unlikely that this defect lies at the level of GR polymorphisms, and probably reflects differences in GR post-translational modifications and association with co-factors and chromatin</p><p>[<a href="#rid47">47</a>]</p><p class="headingAnchor" id="H8"><span class="h2">Interactions with other nucleoproteins and epigenetics</span><span class="headingEndMark"> — </span>Interaction of the nuclear GR-ligand complex with other nucleoproteins modulates GC activity and may be responsible for the DNA binding abnormalities noted above. In one study, the interaction between the GC receptor and the pro-inflammatory transcription factor activator protein (AP)-1 was significantly reduced in GC-resistant patients, although interaction with NF-kappaB was unaffected [<a href="#rid48">48</a>]. An increase in the basal levels of AP-1 DNA binding was also detected in the nuclei from patients with GC-resistant asthma [<a href="#rid9">9</a>]. In addition, a bioinformatic analysis of regulatory networks from cells from asthmatics who were either good or poor responders to ICS, identified AP-1 as a key hub gene for poor GC response [<a href="#rid49">49</a>].</p><p>Epigenetic changes also appear to contribute to GC sensitivity. Reduced HDAC activity and increased histone acetylation have been reported in bronchial biopsies of children with severe GC-resistant asthma [<a href="#rid50">50</a>] and in peripheral blood cells of affected adults [<a href="#rid51">51</a>]. This decrease in HDAC activity may be a result of increased IL-17 since IL-17 reduces GC function in primary human epithelial cells by reducing HDAC [<a href="#rid33">33</a>]. Differences in DNA methylation profiles in both airway smooth muscle cells and airway epithelial cells have also been reported to be liked to asthma severity using weighted gene coexpression network analysis [<a href="#rid52">52,53</a>].</p><p>Expression quantitative trait loci (eQTL) analysis has been performed in epithelial and BAL cells of severe asthmatics to explore the genetic influence on gene expression [<a href="#rid54">54,55</a>]. Many of these eQTLs reside in regulatory elements of genes enriched in the Th2 lymphocyte and IL-33 immune responses and of MUC5AC, particularly in airway epithelial cells [<a href="#rid56">56,57</a>]. Interestingly, IL-13 resets the DNA methylome in human airway epithelial cells to modulate asthma severity–associated pathways [<a href="#rid52">52</a>]. </p><p>A small study looking at peripheral blood transcriptomic profiling of 13 children with GC-resistant asthma identified genes such as RAR-Related Orphan Receptor alpha (RORA) which were known asthma genes by genome wide association studies [<a href="#rid58">58</a>]. This study also highlighted the importance of decreased GR signaling and increased MAPK and Jun N-terminal kinase (JNK) activity in these children with GC-resistant asthma. Decreased GR expression along with impaired nuclear translocation is associated with attenuated GC-responsiveness in airway smooth muscle [<a href="#rid59">59</a>] and peripheral blood monocytes from patients with GC-resistant asthma [<a href="#rid60">60</a>]. In blood cells this has been linked to reduced histone acetylation at the MAPK phosphatase-1 (MKP-1) promoter and MKP-1 induction by <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid60">60</a>]. This in turn may result in the reduced ability to attenuate mitogen-induced phospho-p38 MAPK activity which has been reported in peripheral blood CD14+ monocytes, but not CD4+ or CD8+ T lymphocytes, from GC-resistant asthmatics [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/561.html" rel="external">"Genetics of asthma"</a>.)</p><p>Analysis of transcriptomic profiles in bronchial epithelial cells and brushings indicated a group of patients with high levels of tissue eosinophilia and Th2 cytokines who also expressed high levels of steroid-sensitive genes despite being treated with high doses of inhaled and oral GCs [<a href="#rid62">62</a>]. Specific pathways associated with airway remodelling such as matrix metalloprotease 10 (MMP10) and hepatocyte growth factor (MET) provide potential targets for intervention and the control of airway hyperresponsiveness which is important clinically [<a href="#rid63">63</a>]. In SARP, asthmatics with persistently high Th2 inflammation were older and had more severe disease. Body weight had a major impact on blood biomarker expression in these subjects [<a href="#rid64">64</a>]. </p><p>Oxidative and nitrosative stress levels are high in patients with GC-insensitive asthma and oxidative stress has been shown to reduce GR translocation in primary human airway fibroblasts [<a href="#rid65">65</a>]. This effect of oxidative stress may be important in asthmatic subjects who smoke as these patients do not respond well to either high dose inhaled or oral GCs [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H17433872"><span class="h2">Viral and bacterial infections</span><span class="headingEndMark"> — </span>The role of viral and bacterial infection in modulating GC responsiveness is becoming increasingly evident. Both rhinovirus and respiratory syncytial virus can induce a degree of GC insensitivity in primary bronchial epithelial cells following activation of pro-inflammatory signalling pathways [<a href="#rid67">67</a>]. </p><p>The airway microbiome in patients with severe asthma differs from that seen in patients with milder disease and may be an additional contributor to abnormalities in GC sensitivity [<a href="#rid68">68</a>]. In a study of bacterial RNA in bronchial brushings, samples from patients with GC-resistant asthma were significantly enriched in <em>Actinobacteria</em> and a <em>Klebsiella</em> genus member although dysbiosis was also associated with different sub-phenotypes of GC-resistant asthma. Thus, patients with worse Asthma Control Questionnaire (ACQ) scores and higher sputum total leukocyte values had a greater predominance of Proteobacteria, whereas those with a high body mass index (BMI) were associated with greater levels of Bacteroidetes/Firmicutes.</p><p>In addition, bacterial clearance from the airways of severe GC-resistant asthmatics may be defective. Monocyte-derived macrophages from patients with GC-resistant asthma are less able to phagocytose <em>Haemophilus influenzae</em> and <em>Staphylococcus aureus</em> than those from non-severe asthmatics [<a href="#rid69">69</a>]. </p><p>Importantly, the influence of the airway microbiome in glucocorticoid responsiveness in asthma has also been reported [<a href="#rid70">70</a>]. In a study that compared bacteria in the bronchoalveolar lavage samples from subjects with GC-resistant and GC-sensitive asthma, expansion of specific gram-negative bacteria including <em>Haemophilus parainfluenzae</em>, which induce GC resistance through p38 MAPK activation was noted in a subset of subjects with GC-resistant asthma, but not in subjects with GC-sensitive asthma. However, inhibition of transforming growth factor-beta-associated kinase-1 (TAK1), but not p38 MAPK, restored cellular sensitivity to GCs.</p><p>Unbiased hierarchical clustering of differentially expressed genes in sputum of severe and moderate asthmatics identified three transcriptome-associated clusters (TACs). TAC1 was characterized by IL33R, CCR3, and TSLPR receptors and highest enrichment of the Th2high signature; TAC2 was characterized by IFN and inflammasome-associated genes; and TAC3 was characterized by metabolic genes and normal mitochondrial function [<a href="#rid71">71</a>]. Inflammasome activation in TAC2 was linked with sputum neutrophilia, asthma severity and with high sputum IL-1beta protein levels [<a href="#rid72">72</a>]. The presence of neutrophils and inflammasome activation suggests the potential presence of sub-clinical infection or microbial dysbiosis in these patients [<a href="#rid73">73</a>]. Interestingly, the macrolide antibiotic <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> given for 48 weeks reduced exacerbations and improved asthma quality of life and may be a useful therapy for these patients [<a href="#rid74">74</a>]. </p><p>Topological data analysis of asthma sputum proteomics and transcriptomics revealed 10 subdivisions of asthma phenotypes and highlighted three distinct groups of eosinophilic and neutrophilic asthmatics with separate protein, gene, and clinical features.</p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with glucocorticoid (GC)-resistant asthma were first reported in 1967 [<a href="#rid75">75</a>]. These patients typically have severe asthma, but extrapulmonary glucocorticoid function is largely normal.</p><p class="headingAnchor" id="H1471873947"><span class="h2">Asthma</span><span class="headingEndMark"> — </span>Patients with GC-resistant asthma have a phenotype of severe asthma  (<a class="graphic graphic_table graphicRef68983" href="/z/d/graphic/68983.html" rel="external">table 2</a>) [<a href="#rid4">4</a>] and require high-dose inhaled glucocorticoids and sometimes chronic use of oral glucocorticoids. (See <a class="local">'Definition'</a> above and  <a class="medical medical_review" href="/z/d/html/564.html" rel="external">"Evaluation of severe asthma in adolescents and adults"</a>.)</p><p>In both the Severe Asthma Research Program (SARP) and the Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED) cohorts, at least 30 percent of patients with severe asthma required regular use of oral GCs to maintain asthma control [<a href="#rid76">76</a>]. These patients appeared to be relatively, rather than absolutely, GC insensitive based on the presence of a response to higher doses of systemic glucocorticoids (ie, <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 120 mg, intramuscularly) [<a href="#rid77">77</a>]. The features of severe asthma in general are described separately. (See  <a class="medical medical_review" href="/z/d/html/564.html" rel="external">"Evaluation of severe asthma in adolescents and adults", section on 'History and physical'</a>.)</p><p>Among patients who require high-dose inhaled glucocorticoids or chronic oral glucocorticoids to maintain asthma control, approximately 50 percent have persistent airflow limitation and 69 percent have sputum eosinophilia (defined as ≥2 percent eosinophils) [<a href="#rid76">76,78</a>]. A subset of patients with frequent oral GC use has late onset asthma, obesity, and moderate reductions in the forced expiratory volume in one second (FEV<sub>1</sub>). A case series of 58 asthmatic subjects who were clinically resistant to <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> therapy described a longer duration of asthma, poorer morning lung function, and a greater degree of bronchial reactivity than GC-sensitive asthmatics [<a href="#rid79">79</a>]. </p><p>Clustering on clinical features of severe asthmatics has revealed subsets of severe asthmatics but no specific group was associated with GC-insensitive asthma or identified key driver mechanisms [<a href="#rid80">80,81</a>]. GC responsiveness may vary over time in a given individual depending on factors such as cigarette smoking, viral infections, and allergen exposure. A portion of patients who appear GC-insensitive have been found to be nonadherent with oral GC therapy [<a href="#rid82">82</a>]. </p><p class="headingAnchor" id="H10"><span class="h2">Extrapulmonary glucocorticoid responses</span><span class="headingEndMark"> — </span>Abnormalities associated with GC resistance may be elicited in the skin but tend not to be significant in other extrapulmonary sites (eg, adrenal, bone). As an example, the cutaneous vasoconstrictor response to <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a> dipropionate is significantly reduced in patients with GC-resistant asthma [<a href="#rid83">83</a>]. This pattern of reduced sensitivity in the lung and in skin blanching, but not in other extrapulmonary sites suggests that this is a defect in the anti-inflammatory effects of GCs, but not in metabolic or endocrine effects. In addition, these patients still develop Cushingoid symptoms.</p><p>The hypothalamic-pituitary-adrenal axis appears normal among patients with GC-resistant asthma, as reflected by the levels of urinary free cortisol and plasma adrenocorticotropic hormone (ACTH). Cortisol measurements and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> suppression responses are normal. (See  <a class="medical medical_review" href="/z/d/html/160.html" rel="external">"Dexamethasone suppression tests"</a>.)</p><p>GCs cause similar changes in bone metabolism in GC-sensitive and GC-resistant patients. One study compared the effects of five days of treatment with daily <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> upon markers of bone turnover in six persons with GC-sensitive and six patients with GC-resistant asthma [<a href="#rid84">84</a>]. No significant differences before or following treatment were observed between the two groups in serum osteocalcin, tartrate resistant acid phosphatase, and alkaline phosphatase, or urinary free deoxypyridinoline.</p><p>Before a diagnosis of GC-resistant asthma is made, a number of other entities that are in the differential diagnosis of severe asthma <strong>must</strong> be excluded and patients must be assessed for compliance with therapy [<a href="#rid82">82,85</a>]. The evaluation of these disorders is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/563.html" rel="external">"Evaluation of wheezing illnesses other than asthma in adults"</a> and  <a class="medical medical_review" href="/z/d/html/564.html" rel="external">"Evaluation of severe asthma in adolescents and adults"</a>.):</p><p class="headingAnchor" id="H3656784489"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Patients with severe asthma who require oral glucocorticoids (GCs) to achieve asthma control or whose asthma remains poorly controlled despite oral GCs should be evaluated following guidelines for severe asthma [<a href="#rid4">4,86</a>] to exclude alternative diagnoses, comorbid diseases, compliance and confounding issues that may exacerbate asthma. The term GC-resistant asthma refers to patients at the less responsive end of a spectrum of GC sensitivity, but is not an actual diagnosis. (See  <a class="medical medical_review" href="/z/d/html/564.html" rel="external">"Evaluation of severe asthma in adolescents and adults"</a>.)</p><p>The majority of patients who meet criteria for severe asthma are relatively insensitive to GCs, rather than completely GC-resistant. As GC-resistance is almost always relative, and because such a designation does not clearly affect the treatment approach, specific testing to establish GC-insensitivity is not needed. (See <a class="local">'Definition'</a> above.)</p><p>For the rare patients with suspected true GC-resistance on the basis of an absence of Cushingoid features despite ongoing oral GCs, laboratory testing may be helpful in determining whether the patient is nonadherent or GC-resistant. Alternatively, assessing response to intramuscular <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> is sometimes used to determine whether nonadherence is contributing to a lack of response. </p><p class="headingAnchor" id="H2557427470"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Specific laboratory testing for glucocorticoid resistance is largely a research tool, and complete GC resistance is rare. </p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have no response to two weeks of oral GCs (eg, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 mg/day), one way to assess nonadherence is by checking a serum level of <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> or morning serum cortisol, but this is rarely necessary. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Research suggests that GC resistance in asthma <strong>cannot</strong> be explained by malabsorption or pharmacokinetic mechanisms, so assessment of absorption and clearance kinetics is unlikely to be helpful. (See <a class="local">'Mechanisms of glucocorticoid resistance'</a> above and  <a class="medical medical_review" href="/z/d/html/161.html" rel="external">"Measurement of cortisol in serum and saliva", section on 'Measurement of serum cortisol'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Familial GC resistance due to a missense mutation of the glucocorticoid receptor (GR) hormone binding domain causes global insensitivity to GC action and leads hyperandrogenism, but is not associated with GC-resistance in asthma [<a href="#rid10">10,87</a>]. Thus, we do not test for this abnormality. (See  <a class="medical medical_review" href="/z/d/html/123.html" rel="external">"Adrenal hyperandrogenism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of sputum eosinophils or exhaled nitric oxide may help to predict which patients would be expected to respond to increased GC doses, although data are conflicting [<a href="#rid85">85</a>]. As an example, a fraction of exhaled nitric oxide (FE<sub>NO</sub>) &gt;50 ppb suggests GC responsive airway inflammation, while a FE<sub>NO</sub> &lt;25 ppb implies an absence of eosinophilic airway inflammation and a low likelihood of GC response. (See  <a class="medical medical_review" href="/z/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications", section on 'Clinical use of FENO in asthma'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">IMPLICATIONS FOR TREATMENT</span><span class="headingEndMark"> — </span>Management of patients with glucocorticoid (GC)-resistant asthma previously presented unique challenges because of a paucity of effective and well-tolerated alternatives to GCs but the advent of new biological therapies targeting Th2high asthma has proven effective in many subjects [<a href="#rid88">88</a>]. Treatment strategies include avoidance of asthma triggers, use of higher doses and a longer duration of systemic GCs, and optimization of non-GC medications (eg, beta adrenergic agonists, antileukotriene agents, muscarinic antagonists, <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>, <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>) and nonpharmacologic methods. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/562.html" rel="external">"Trigger control to enhance asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma"</a> and  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy"</a>.) </p><p class="headingAnchor" id="H2997288348"><span class="h2">Oral and parenteral glucocorticoids</span><span class="headingEndMark"> — </span>Because resistance to inhaled and systemic GCs tends to be relative rather than absolute, patients may respond to systemic GCs when given at higher doses or for a longer duration than required by other patients with asthma [<a href="#rid4">4</a>]. While systemic GCs remain the treatment of choice for asthma exacerbations, every effort should be made to avoid long-term use of systemic GCs for asthma management [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Systemic glucocorticoids'</a>.)</p><p>For patients who do not appear to respond to high-dose inhaled GC or oral GC, a therapeutic trial of <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> can be administered 120 mg, intramuscularly, as a single dose [<a href="#rid77">77</a>]. Studies in adults and children show a variable response with 20 percent showing a 10 percent improvement in lung function but indicating a non-responsive pathobiology [<a href="#rid90">90</a>]. Importantly, there appears to be an ethnic difference in the fraction of exhaled nitric oxide (FE<sub>NO</sub>) and exacerbation responses to triamcinolone, which are less evident in Black children compared with White children [<a href="#rid91">91</a>]. The mechanism for this difference is unknown. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Systemic glucocorticoids'</a>.)  </p><p>While the mechanisms for GC insensitivity are heterogeneous, inflammation may contribute to a lack of response to GCs through increases in the proinflammatory transcription factor activation protein (AP)-1 and elevated levels of interleukin (IL)-2 and IL-4. If this hypothesis is correct, <strong>early</strong> <strong>use</strong> of GCs might suppress inflammation and preserve GC sensitivity [<a href="#rid92">92</a>]. In addition, a course of systemic GCs may reduce airways inflammation enough that the patient becomes responsive to inhaled GCs.</p><p class="headingAnchor" id="H947130185"><span class="h2">Inhaled glucocorticoids</span><span class="headingEndMark"> — </span>Patients with severe asthma are relatively refractory to inhaled GCs and require high-dose inhaled GCs to maintain asthma control. When asthma is not well controlled on high dose inhaled GC (eg, about 1000 mcg per day), but appears to be GC responsive, we consider a further increase in dose or use of an inhaled GC with a smaller particle size. The evidence for increasing the dose of inhaled GC above 1000 mcg per day is limited and not all patients will improve with higher inhaled GC doses. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Inhaled glucocorticoids'</a>.)</p><p>Some work has shown that GC sensitivity may vary over time, so it is clinically prudent to institute a trial of a higher dose of inhaled GC at regular intervals even if they have not been effective when tried previously [<a href="#rid93">93</a>]. At some point, assessment of airway eosinophilia (eg, sputum eosinophils, increased FE<sub>NO</sub>) may become a useful tool to assess whether a patient might respond to a higher dose of inhaled GCs, although further study is needed to determine the exact biomarkers and parameters [<a href="#rid85">85,94,95</a>]. (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes", section on 'Phenotyping based on biomarkers of inflammation'</a>.)</p><p class="headingAnchor" id="H2907553148"><span class="h2">Non-glucocorticoid agents</span><span class="headingEndMark"> — </span>Patients with relative GC-resistance may respond better to non-GC treatments for asthma than to GCs, depending on their asthma phenotype. Non-glucocorticoid agents include long-acting beta agonists, long-acting muscarinic antagonists, leukotriene-modifying agents, anti-immunoglobulin E therapy (<a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>), anti-interleukin-5 (anti-IL-5) therapy (<a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>, <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>), and anti-IL-4/13 therapy (<a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>). (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes"</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Adjusting controller therapy'</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Persistently uncontrolled asthma'</a> and  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy"</a>.) </p><p>Allergen immunotherapy has not proved effective in these patients and has considerable side effect issues [<a href="#rid96">96</a>]. </p><p>Research to identify phenotypes among patients with severe asthma may help guide selection of appropriate agents. (See <a class="local">'Future directions'</a> below and  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes"</a>.)</p><p class="headingAnchor" id="H4081151399"><span class="h2">Nonpharmacologic management</span><span class="headingEndMark"> — </span>Proper nonpharmacologic management is critical in GC-resistant individuals. Close follow-up and frequent communication between patient and clinician are advisable. </p><p class="bulletIndent1"><span class="glyph">●</span>Precipitants of bronchospasm should be identified, and specific recommendations regarding trigger avoidance should be given  (<a class="graphic graphic_table graphicRef58870" href="/z/d/graphic/58870.html" rel="external">table 3</a>). For patients who continue to smoke cigarettes, every effort should be made to achieve smoking cessation. (See  <a class="medical medical_review" href="/z/d/html/562.html" rel="external">"Trigger control to enhance asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be educated regarding the nature of their disease, and correct inhaler technique should be periodically reinforced. (See  <a class="medical medical_review" href="/z/d/html/566.html" rel="external">"Asthma education and self-management"</a> and  <a class="medical medical_review" href="/z/d/html/552.html" rel="external">"Delivery of inhaled medication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/559.html" rel="external">"The use of inhaler devices in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bronchial thermoplasty involves targeted application of heat (via radiofrequency waves) to the airways and may be of benefit in selected adults with severe asthma that is not well-controlled with inhaled GCs and long-acting beta agonists. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Bronchial thermoplasty'</a>.)</p><p></p><p class="headingAnchor" id="H2196100398"><span class="h1">FUTURE DIRECTIONS</span><span class="headingEndMark"> — </span>Current research is focused on identifying non-glucocorticoid (GC) immunomodulatory agents that target pathways of inflammation in asthma and determining which patients are most likely to respond to specific therapies. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational therapies</strong> – New drugs are being developed to target other pathways of asthma inflammation [<a href="#rid97">97</a>], such as interleukins and their receptors, chemokine receptor homologous molecule expressed on T helper type 2 cells (CRTh2), and also chemokine receptors, such as the C-C chemokine receptor, CCR3 [<a href="#rid97">97</a>]. Investigational agents for asthma are discussed in detail separately. (See <a class="local">'Altered cytokine expression'</a> above and  <a class="medical medical_review" href="/z/d/html/526.html" rel="external">"Investigational agents for asthma"</a>.)</p><p></p><p class="bulletIndent1">Another line of investigation is to identify agents that work alone or in combination with glucocorticoids to overcome GC resistance, and thus re-establish essential anti-inflammatory mechanisms. Examples include agents that restore histone deacetylase activity (HDAC), or agents that inhibit phosphorylation of the glucocorticoid receptor (GR) via inhibiting p38 mitogen activated protein kinase (p38 MAPK) or other kinases [<a href="#rid98">98</a>]. (See <a class="local">'Mechanisms of glucocorticoid resistance'</a> above.)</p><p></p><p class="bulletIndent1">Calcitriol, the active form of vitamin D (1alpha,25-dihydroxyvitamin D3), influences IL-10 production and may play a role in GC sensitivity in asthma [<a href="#rid29">29,99</a>]. Calcitriol restores the impaired IL-10 synthesis observed in GC refractory asthma patients, both in vitro and after oral administration for one week [<a href="#rid29">29</a>]. Children with GC-resistant asthma have reduced serum levels of vitamin D, and this correlates with the forced expiratory volume in one second (FEV<sub>1</sub>) percent predicted, Asthma Control Test (ACT test) scores, and bronchodilator reversibility, as well as inversely correlating with exacerbations and inhaled GC usage [<a href="#rid100">100</a>]. (See <a class="local">'Altered cytokine expression'</a> above.)</p><p></p><p class="bulletIndent1">Specific agents that improve asthma by targeting mechanisms of neutrophilic asthma have not been identified [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes", section on 'Neutrophilic asthma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of biomarkers to guide treatment</strong> – Asthma is a syndrome with many potential phenotypes or endotypes that may help to determine the most effective therapeutic regimen suitable for each patient; it is therefore necessary to stratify patients accordingly [<a href="#rid102">102</a>]. Several large groups such as the Severe Asthma Research Program (SARP) and Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED), as well as individual centers, have been instrumental in defining these subgroups of asthma and severe asthma [<a href="#rid103">103</a>]. These subgroups include for example the T helper lymphocyte (Th2) high and Th2 low groups [<a href="#rid104">104</a>]. Th2 high asthma is inversely correlated with the presence of IL-17/Th17 high [<a href="#rid31">31,32</a>] and IL-6 trans-signaling (IL6TS) high groups [<a href="#rid44">44</a>] and a group with high expression of IFN-stimulated genes (ISGs) [<a href="#rid41">41</a>] in the absence of viral infection. There is also a group of obese asthmatics with severe disease [<a href="#rid105">105</a>]. The American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines highlight the need for greater understanding of severe asthma, disease stratification, and determination of treatment efficacy [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes"</a>.)</p><p></p><p class="bulletIndent1">Some studies have assessed the efficacy of certain biomarkers to guide selection of asthma therapy. Patients who are not well-controlled despite high dose inhaled or oral GCs and who exhibit high sputum and blood eosinophils and high levels of FE<sub>NO</sub> may respond better to anti-IL-5-directed therapies or <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> with respect to exacerbation frequency and oral GC use [<a href="#rid106">106-109</a>]. The potential role of novel biologic agents in the treatment of asthma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes"</a> and  <a class="medical medical_review" href="/z/d/html/526.html" rel="external">"Investigational agents for asthma", section on 'Biologic agents'</a>.)</p><p></p><p class="bulletIndent1">Measurements of exhaled metabolites (electronic nose) and urinary eicosanoids may help characterize the inflammatory profile of patients with severe asthma and differentiate those that may respond to anti-Th2 or non-Th2 therapies [<a href="#rid110">110,111</a>].</p><p></p><p class="headingAnchor" id="H5655421"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of GC-resistance</strong> – Glucocorticoid (GC) responsiveness represents a continuous spectrum; patients with chronic asthma who are unresponsive to high doses of GCs and are <strong>without confounding factors </strong>have been termed GC-resistant. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of GC-resistance</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients who require high-dose inhaled glucocorticoids or chronic oral glucocorticoids to maintain asthma control, approximately 50 percent have persistent airflow limitation and 69 percent have sputum eosinophilia (defined as ≥2 percent eosinophils). While the cutaneous vasoconstrictor response to topical glucocorticoid is significantly reduced, other tissues (eg, adrenal, bone) do not appear to have an abnormal GC response. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with GC-resistant asthma, the function of the hypothalamic-pituitary-adrenal axis appears normal. Serum cortisol measurements and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> suppression responses are normal, and GC-induced side-effects are a major issue. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Patients with severe asthma who require oral GCs to achieve asthma control or whose asthma remains poorly controlled despite oral GCs should be evaluated following guidelines for severe asthma to exclude alternative diagnoses, comorbid diseases, and confounding issues that may exacerbate asthma. As GC-resistance is almost always relative and does not clearly affect the treatment approach, specific testing to establish GC-insensitivity is not needed. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GC resistance in asthma cannot be explained by malabsorption or pharmacokinetic mechanisms. Defects in GC-glucocorticoid receptor (GR) binding, GR nuclear translocation, and intranuclear actions of GR have all been proposed as major mechanisms for GC resistance  (<a class="graphic graphic_figure graphicRef67246" href="/z/d/graphic/67246.html" rel="external">figure 1</a>). (See <a class="local">'Mechanisms of glucocorticoid action'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The exact mechanism of GC resistance in asthma is not known. Possible mechanisms include altered splicing of the GR premessenger RNA, altered proinflammatory cytokine expression, a reduced number of GRs, and epigenetic changes  (<a class="graphic graphic_figure graphicRef88276" href="/z/d/graphic/88276.html" rel="external">figure 2</a>). (See <a class="local">'Mechanisms of glucocorticoid resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Implications for treatment</strong> – The optimal treatment for GC-resistant asthma is not known. Treatment strategies should aim to reduce the total exposure to systemic GCs using a pulsed approach and optimization of non-GC agents (eg, long-acting beta-adrenergic agonists, long-acting muscarinic antagonists, antileukotriene agents), nonpharmacologic therapies (eg, trigger avoidance and possibly bronchial thermoplasty), and targeted biological therapies (<a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>, <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a>, <a class="drug drug_general" data-topicid="134676" href="/z/d/drug information/134676.html" rel="external">tezepelumab</a>). (See <a class="local">'Implications for treatment'</a> above and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/526.html" rel="external">"Investigational agents for asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Future directions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New drugs are being developed that target other pathways of asthma inflammation, such as interleukins and their receptors and chemokine receptors (eg, C-C chemokine receptor, CCR3), or that prevent oxidative stress. Biomarkers of adherence to therapy, eosinophilic and noneosinophilic phenotypes of severe asthma, and predictors of response to novel therapeutic agents are also in development. (See <a class="local">'Future directions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Biomarkers of compliance and predictors of response to therapeutic agents are needed. Examples of biomarkers being developed are dipeptidyl-peptidase (DPP)4 and FK506 Binding Protein (FKBP)5. (See <a class="local">'Future directions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Mensah GA, Kiley JP, Gibbons GH. Generating evidence to inform an update of asthma clinical practice guidelines: Perspectives from the National Heart, Lung, and Blood Institute. J Allergy Clin Immunol 2018; 142:744.</a></li><li class="breakAll">2023 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. www.ginasthma.org/2023-gina-main-report (Accessed on May 15, 2023).</li><li><a class="nounderline abstract_t">Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343.</a></li><li><a class="nounderline abstract_t">Adcock IM, Gilbey T, Gelder CM, et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996; 154:771.</a></li><li><a class="nounderline abstract_t">Adcock IM, Mumby S. Glucocorticoids. Handb Exp Pharmacol 2017; 237:171.</a></li><li><a class="nounderline abstract_t">Surjit M, Ganti KP, Mukherji A, et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011; 145:224.</a></li><li><a class="nounderline abstract_t">Saraiva M, Vieira P, O'Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med 2020; 217.</a></li><li><a class="nounderline abstract_t">Biddie SC, John S, Sabo PJ, et al. Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol Cell 2011; 43:145.</a></li><li><a class="nounderline abstract_t">Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20:6891.</a></li><li><a class="nounderline abstract_t">Galliher-Beckley AJ, Williams JG, Cidlowski JA. Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol 2011; 31:4663.</a></li><li><a class="nounderline abstract_t">Wan YI, Shrine NR, Soler Artigas M, et al. Genome-wide association study to identify genetic determinants of severe asthma. Thorax 2012; 67:762.</a></li><li><a class="nounderline abstract_t">Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011; 365:1173.</a></li><li><a class="nounderline abstract_t">Zhao F, Zhou G, Ouyang H, et al. Association of the glucocorticoid receptor D641V variant with steroid-resistant asthma: a case-control study. Pharmacogenet Genomics 2015; 25:289.</a></li><li><a class="nounderline abstract_t">Zein J, Gaston B, Bazeley P, et al. HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma. Proc Natl Acad Sci U S A 2020; 117:2187.</a></li><li><a class="nounderline abstract_t">Lu NZ, Cidlowski JA. Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes. Mol Cell 2005; 18:331.</a></li><li><a class="nounderline abstract_t">Goleva E, Li LB, Eves PT, et al. Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 2006; 173:607.</a></li><li><a class="nounderline abstract_t">Vazquez-Tello A, Semlali A, Chakir J, et al. Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines. Clin Exp Allergy 2010; 40:1312.</a></li><li><a class="nounderline abstract_t">Christodoulopoulos P, Leung DY, Elliott MW, et al. Increased number of glucocorticoid receptor-beta-expressing cells in the airways in fatal asthma. J Allergy Clin Immunol 2000; 106:479.</a></li><li><a class="nounderline abstract_t">Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol 2000; 105:782.</a></li><li><a class="nounderline abstract_t">Ducharme FM, Lemire C, Noya FJ, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009; 360:339.</a></li><li><a class="nounderline abstract_t">Panickar J, Lakhanpaul M, Lambert PC, et al. Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med 2009; 360:329.</a></li><li><a class="nounderline abstract_t">Hinzey A, Alexander J, Corry J, et al. Respiratory syncytial virus represses glucocorticoid receptor-mediated gene activation. Endocrinology 2011; 152:483.</a></li><li><a class="nounderline abstract_t">Leung DY, Martin RJ, Szefler SJ, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med 1995; 181:33.</a></li><li><a class="nounderline abstract_t">Kam JC, Szefler SJ, Surs W, et al. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993; 151:3460.</a></li><li><a class="nounderline abstract_t">Bhavsar P, Khorasani N, Hew M, et al. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J 2010; 35:750.</a></li><li><a class="nounderline abstract_t">Goleva E, Li LB, Leung DY. IFN-gamma reverses IL-2- and IL-4-mediated T-cell steroid resistance. Am J Respir Cell Mol Biol 2009; 40:223.</a></li><li><a class="nounderline abstract_t">O'Garra A, Barrat FJ, Castro AG, et al. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008; 223:114.</a></li><li><a class="nounderline abstract_t">Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006; 116:146.</a></li><li><a class="nounderline abstract_t">Gupta A, Dimeloe S, Richards DF, et al. Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma. Thorax 2014; 69:508.</a></li><li><a class="nounderline abstract_t">Choy DF, Hart KM, Borthwick LA, et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 2015; 7:301ra129.</a></li><li><a class="nounderline abstract_t">Östling J, van Geest M, Schofield JPR, et al. IL-17-high asthma with features of a psoriasis immunophenotype. J Allergy Clin Immunol 2019; 144:1198.</a></li><li><a class="nounderline abstract_t">Zijlstra GJ, Ten Hacken NH, Hoffmann RF, et al. Interleukin-17A induces glucocorticoid insensitivity in human bronchial epithelial cells. Eur Respir J 2012; 39:439.</a></li><li><a class="nounderline abstract_t">Nanzer AM, Chambers ES, Ryanna K, et al. Enhanced production of IL-17A in patients with severe asthma is inhibited by 1α,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion. J Allergy Clin Immunol 2013; 132:297.</a></li><li><a class="nounderline abstract_t">Saglani S, Lui S, Ullmann N, et al. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol 2013; 132:676.</a></li><li><a class="nounderline abstract_t">Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol 2021; 148:790.</a></li><li><a class="nounderline abstract_t">Tiotiu A, Badi Y, Kermani NZ, et al. Association of Differential Mast Cell Activation with Granulocytic Inflammation in Severe Asthma. Am J Respir Crit Care Med 2022; 205:397.</a></li><li><a class="nounderline abstract_t">Watanabe M, Nakamoto K, Inui T, et al. Soluble ST2 enhances IL-33-induced neutrophilic and pro-type 2 inflammation in the lungs. Allergy 2022; 77:3137.</a></li><li><a class="nounderline abstract_t">Badi YE, Salcman B, Taylor A, et al. IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma. Allergy 2023; 78:156.</a></li><li><a class="nounderline abstract_t">Raundhal M, Morse C, Khare A, et al. High IFN-γ and low SLPI mark severe asthma in mice and humans. J Clin Invest 2015; 125:3037.</a></li><li><a class="nounderline abstract_t">Bhakta NR, Christenson SA, Nerella S, et al. IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma. Am J Respir Crit Care Med 2018; 197:313.</a></li><li><a class="nounderline abstract_t">Gauthier M, Kale SL, Oriss TB, et al. Dual role for CXCR3 and CCR5 in asthmatic type 1 inflammation. J Allergy Clin Immunol 2022; 149:113.</a></li><li><a class="nounderline abstract_t">Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med 2016; 4:574.</a></li><li><a class="nounderline abstract_t">Jevnikar Z, Östling J, Ax E, et al. Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. J Allergy Clin Immunol 2019; 143:577.</a></li><li><a class="nounderline abstract_t">Hinks T, Zhou X, Staples K, et al. Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data. Lancet 2015; 385 Suppl 1:S42.</a></li><li><a class="nounderline abstract_t">Adcock IM, Lane SJ, Brown CR, et al. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 1995; 154:3500.</a></li><li><a class="nounderline abstract_t">Kabesch M, Adcock IM. Epigenetics in asthma and COPD. Biochimie 2012; 94:2231.</a></li><li><a class="nounderline abstract_t">Adcock IM, Lane SJ, Brown CR, et al. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 1995; 182:1951.</a></li><li><a class="nounderline abstract_t">Qiu W, Guo F, Glass K, et al. Differential connectivity of gene regulatory networks distinguishes corticosteroid response in asthma. J Allergy Clin Immunol 2018; 141:1250.</a></li><li><a class="nounderline abstract_t">Su RC, Becker AB, Kozyrskyj AL, Hayglass KT. Altered epigenetic regulation and increasing severity of bronchial hyperresponsiveness in atopic asthmatic children. J Allergy Clin Immunol 2009; 124:1116.</a></li><li><a class="nounderline abstract_t">Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 2006; 174:134.</a></li><li><a class="nounderline abstract_t">Nicodemus-Johnson J, Naughton KA, Sudi J, et al. Genome-Wide Methylation Study Identifies an IL-13-induced Epigenetic Signature in Asthmatic Airways. Am J Respir Crit Care Med 2016; 193:376.</a></li><li><a class="nounderline abstract_t">Perry MM, Lavender P, Kuo CS, et al. DNA methylation modules in airway smooth muscle are associated with asthma severity. Eur Respir J 2018; 51.</a></li><li><a class="nounderline abstract_t">Luo W, Obeidat M, Di Narzo AF, et al. Airway Epithelial Expression Quantitative Trait Loci Reveal Genes Underlying Asthma and Other Airway Diseases. Am J Respir Cell Mol Biol 2016; 54:177.</a></li><li><a class="nounderline abstract_t">Li X, Hastie AT, Hawkins GA, et al. eQTL of bronchial epithelial cells and bronchial alveolar lavage deciphers GWAS-identified asthma genes. Allergy 2015; 70:1309.</a></li><li><a class="nounderline abstract_t">Ketelaar ME, Portelli MA, Dijk FN, et al. Phenotypic and functional translation of IL33 genetics in asthma. J Allergy Clin Immunol 2021; 147:144.</a></li><li><a class="nounderline abstract_t">Shrine N, Portelli MA, John C, et al. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. Lancet Respir Med 2019; 7:20.</a></li><li><a class="nounderline abstract_t">Persson H, Kwon AT, Ramilowski JA, et al. Transcriptome analysis of controlled and therapy-resistant childhood asthma reveals distinct gene expression profiles. J Allergy Clin Immunol 2015; 136:638.</a></li><li><a class="nounderline abstract_t">Chang PJ, Michaeloudes C, Zhu J, et al. Impaired nuclear translocation of the glucocorticoid receptor in corticosteroid-insensitive airway smooth muscle in severe asthma. Am J Respir Crit Care Med 2015; 191:54.</a></li><li><a class="nounderline abstract_t">Zhang Y, Leung DY, Goleva E. Anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma. J Allergy Clin Immunol 2014; 133:1744.</a></li><li><a class="nounderline abstract_t">Li LB, Leung DY, Goleva E. Activated p38 MAPK in Peripheral Blood Monocytes of Steroid Resistant Asthmatics. PLoS One 2015; 10:e0141909.</a></li><li><a class="nounderline abstract_t">Kuo CS, Pavlidis S, Loza M, et al. A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. Am J Respir Crit Care Med 2017; 195:443.</a></li><li><a class="nounderline abstract_t">Kuo CS, Pavlidis S, Zhu J, et al. Contribution of airway eosinophils in airway wall remodeling in asthma: Role of MMP-10 and MET. Allergy 2019; 74:1102.</a></li><li><a class="nounderline abstract_t">Stephenson ST, Brown LA, Helms MN, et al. Cysteine oxidation impairs systemic glucocorticoid responsiveness in children with difficult-to-treat asthma. J Allergy Clin Immunol 2015; 136:454.</a></li><li><a class="nounderline abstract_t">Okamoto K, Tanaka H, Ogawa H, et al. Redox-dependent regulation of nuclear import of the glucocorticoid receptor. J Biol Chem 1999; 274:10363.</a></li><li><a class="nounderline abstract_t">Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168:1308.</a></li><li><a class="nounderline abstract_t">Papi A, Contoli M, Adcock IM, et al. Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κB and c-Jun N-terminal kinase activation. J Allergy Clin Immunol 2013; 132:1075.</a></li><li><a class="nounderline abstract_t">Huang YJ, Nariya S, Harris JM, et al. The airway microbiome in patients with severe asthma: Associations with disease features and severity. J Allergy Clin Immunol 2015; 136:874.</a></li><li><a class="nounderline abstract_t">Liang Z, Zhang Q, Thomas CM, et al. Impaired macrophage phagocytosis of bacteria in severe asthma. Respir Res 2014; 15:72.</a></li><li><a class="nounderline abstract_t">Goleva E, Jackson LP, Harris JK, et al. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med 2013; 188:1193.</a></li><li><a class="nounderline abstract_t">Kuo CS, Pavlidis S, Loza M, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Rossios C, Pavlidis S, Hoda U, et al. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. J Allergy Clin Immunol 2018; 141:560.</a></li><li><a class="nounderline abstract_t">Abdel-Aziz MI, Brinkman P, Vijverberg SJH, et al. Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months. J Allergy Clin Immunol 2021; 147:123.</a></li><li><a class="nounderline abstract_t">Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390:659.</a></li><li><a class="nounderline abstract_t">Schwartz HJ, Lowell FC, Melby JC. Steroid resistance in bronchial asthma. Ann Intern Med 1968; 69:493.</a></li><li><a class="nounderline abstract_t">Silkoff PE, Moore WC, Sterk PJ. Three Major Efforts to Phenotype Asthma: Severe Asthma Research Program, Asthma Disease Endotyping for Personalized Therapeutics, and Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome. Clin Chest Med 2019; 40:13.</a></li><li><a class="nounderline abstract_t">ten Brinke A, Zwinderman AH, Sterk PJ, et al. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170:601.</a></li><li><a class="nounderline abstract_t">ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744.</a></li><li><a class="nounderline abstract_t">Carmichael J, Paterson IC, Diaz P, et al. Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) 1981; 282:1419.</a></li><li><a class="nounderline abstract_t">Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315.</a></li><li><a class="nounderline abstract_t">Lefaudeux D, De Meulder B, Loza MJ, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol 2017; 139:1797.</a></li><li><a class="nounderline abstract_t">Robinson DS, Campbell DA, Durham SR, et al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22:478.</a></li><li><a class="nounderline abstract_t">Brown PH, Teelucksingh S, Matusiewicz SP, et al. Cutaneous vasoconstrictor response to glucocorticoids in asthma. Lancet 1991; 337:576.</a></li><li><a class="nounderline abstract_t">Lane SJ, Vaja S, Swaminathan R, Lee TH. Effects of prednisolone on bone turnover in patients with corticosteroid resistant asthma. Clin Exp Allergy 1996; 26:1197.</a></li><li><a class="nounderline abstract_t">Heaney LG, Busby J, Bradding P, et al. Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma. Am J Respir Crit Care Med 2019; 199:454.</a></li><li><a class="nounderline abstract_t">Hew M, Menzies-Gow A, Hull JH, et al. Systematic Assessment of Difficult-to-Treat Asthma: Principles and Perspectives. J Allergy Clin Immunol Pract 2020; 8:2222.</a></li><li><a class="nounderline abstract_t">Charmandari E, Kino T, Chrousos GP. Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms. Ann N Y Acad Sci 2004; 1024:168.</a></li><li><a class="nounderline abstract_t">Pavord I, Bahmer T, Braido F, et al. Severe T2-high asthma in the biologics era: European experts' opinion. Eur Respir Rev 2019; 28.</a></li><li><a class="nounderline abstract_t">"How can we minimise the use of regular oral corticosteroids in asthma?" Arnaud Bourdin, Ian Adcock, Patrick Berger, Philippe Bonniaud, Philippe Chanson, Cécile Chenivesse, Jacques de Blic, Antoine Deschildre, Philippe Devillier, Gilles Devouassoux, Alain Didier, Gilles Garcia, Antoine Magnan, Yan Martinat, Thierry Perez, Nicolas Roche, Camille Taillé, Pierre Val and Pascal Chanez. Eur Respir Rev 2020; 29: 190085. Eur Respir Rev 2020; 29.</a></li><li><a class="nounderline abstract_t">Phipatanakul W, Mauger DT, Sorkness RL, et al. Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma. Am J Respir Crit Care Med 2017; 195:1439.</a></li><li><a class="nounderline abstract_t">Koo S, Gupta A, Fainardi V, et al. Ethnic Variation in Response to IM Triamcinolone in Children With Severe Therapy-Resistant Asthma. Chest 2016; 149:98.</a></li><li><a class="nounderline abstract_t">Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88:373.</a></li><li><a class="nounderline abstract_t">Demoly P, Jaffuel D, Mathieu M, et al. Glucocorticoid insensitive asthma: a one year clinical follow up pilot study. Thorax 1998; 53:1063.</a></li><li><a class="nounderline abstract_t">Fleming L, Wilson N, Regamey N, Bush A. Use of sputum eosinophil counts to guide management in children with severe asthma. Thorax 2012; 67:193.</a></li><li><a class="nounderline abstract_t">Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67:199.</a></li><li><a class="nounderline abstract_t">Roth-Walter F, Adcock IM, Benito-Villalvilla C, et al. Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases-An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy 2021; 76:90.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2018; 18:454.</a></li><li><a class="nounderline abstract_t">Mei D, Tan WSD, Wong WSF. Pharmacological strategies to regain steroid sensitivity in severe asthma and COPD. Curr Opin Pharmacol 2019; 46:73.</a></li><li><a class="nounderline abstract_t">Jolliffe DA, Stefanidis C, Wang Z, et al. Vitamin D Metabolism Is Dysregulated in Asthma and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2020; 202:371.</a></li><li><a class="nounderline abstract_t">Gupta A, Sjoukes A, Richards D, et al. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med 2011; 184:1342.</a></li><li><a class="nounderline abstract_t">Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol 2015; 135:299.</a></li><li><a class="nounderline abstract_t">Chung KF, Adcock IM. How variability in clinical phenotypes should guide research into disease mechanisms in asthma. Ann Am Thorac Soc 2013; 10 Suppl:S109.</a></li><li><a class="nounderline abstract_t">Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66:910.</a></li><li><a class="nounderline abstract_t">Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388.</a></li><li><a class="nounderline abstract_t">Gibeon D, Batuwita K, Osmond M, et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest 2013; 143:406.</a></li><li><a class="nounderline abstract_t">Shrimanker R, Keene O, Hynes G, et al. Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis. Am J Respir Crit Care Med 2019; 200:1308.</a></li><li><a class="nounderline abstract_t">Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804.</a></li><li><a class="nounderline abstract_t">Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J 2020; 56.</a></li><li><a class="nounderline abstract_t">Papadopoulos NG, Barnes P, Canonica GW, et al. The evolving algorithm of biological selection in severe asthma. Allergy 2020; 75:1555.</a></li><li><a class="nounderline abstract_t">Brinkman P, Wagener AH, Hekking PP, et al. Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma. J Allergy Clin Immunol 2019; 143:1811.</a></li><li><a class="nounderline abstract_t">Kolmert J, Gómez C, Balgoma D, et al. Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. Am J Respir Crit Care Med 2021; 203:37.</a></li></ol></div><div id="topicVersionRevision">Topic 549 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31558662" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30036600" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Generating evidence to inform an update of asthma clinical practice guidelines: Perspectives from the National Heart, Lung, and Blood Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30036600" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Generating evidence to inform an update of asthma clinical practice guidelines: Perspectives from the National Heart, Lung, and Blood Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24337046" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8810618" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Glucocorticoid receptor localization in normal and asthmatic lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864677" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496643" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31611251" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Biology and therapeutic potential of interleukin-10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21726817" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10958685" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21930780" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22561531" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Genome-wide association study to identify genetic determinants of severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21991891" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25815773" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association of the glucocorticoid receptor D641V variant with steroid-resistant asthma: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31932420" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15866175" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16387802" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20545708" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10984367" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Increased number of glucocorticoid receptor-beta-expressing cells in the airways in fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10756230" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19164187" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Preemptive use of high-dose fluticasone for virus-induced wheezing in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19164186" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral prednisolone for preschool children with acute virus-induced wheezing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190962" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Respiratory syncytial virus represses glucocorticoid receptor-mediated gene activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7807013" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8376786" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840967" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18776133" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : IFN-gamma reverses IL-2- and IL-4-mediated T-cell steroid resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18613832" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Strategies for use of IL-10 or its antagonists in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16341266" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24347461" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26290411" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30998987" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : IL-17-high asthma with features of a psoriasis immunophenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21828034" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Interleukin-17A induces glucocorticoid insensitivity in human bronchial epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23683514" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Enhanced production of IL-17A in patients with severe asthma is inhibited by 1α,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759184" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33872652" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34813381" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association of Differential Mast Cell Activation with Granulocytic Inflammation in Severe Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35661175" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Soluble ST2 enhances IL-33-induced neutrophilic and pro-type 2 inflammation in the lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35986608" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26121748" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High IFN-γand low SLPI mark severe asthma in mice and humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29064281" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34146578" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Dual role for CXCR3 and CCR5 in asthmatic type 1 inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27283230" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29902480" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26312864" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7897230" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22874820" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Epigenetics in asthma and COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7500041" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736268" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Differential connectivity of gene regulatory networks distinguishes corticosteroid response in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19895998" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Altered epigenetic regulation and increasing severity of bronchial hyperresponsiveness in atopic asthmatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16614347" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26474238" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Genome-Wide Methylation Study Identifies an IL-13-induced Epigenetic Signature in Asthmatic Airways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29449426" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : DNA methylation modules in airway smooth muscle are associated with asthma severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26102239" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Airway Epithelial Expression Quantitative Trait Loci Reveal Genes Underlying Asthma and Other Airway Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26119467" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : eQTL of bronchial epithelial cells and bronchial alveolar lavage deciphers GWAS-identified asthma genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32442646" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Phenotypic and functional translation of IL33 genetics in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30552067" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25863981" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Transcriptome analysis of controlled and therapy-resistant childhood asthma reveals distinct gene expression profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25411910" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Impaired nuclear translocation of the glucocorticoid receptor in corticosteroid-insensitive airway smooth muscle in severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24418482" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26517722" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Activated p38 MAPK in Peripheral Blood Monocytes of Steroid Resistant Asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27580351" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30667542" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Contribution of airway eosinophils in airway wall remodeling in asthma: Role of MMP-10 and MET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25748343" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cysteine oxidation impairs systemic glucocorticoid responsiveness in children with difficult-to-treat asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10187825" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Redox-dependent regulation of nuclear import of the glucocorticoid receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12893649" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23871663" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factorκB and c-Jun N-terminal kinase activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26220531" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The airway microbiome in patients with severe asthma: Associations with disease features and severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24972601" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Impaired macrophage phagocytosis of bacteria in severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24024497" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The effects of airway microbiome on corticosteroid responsiveness in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28179442" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528200" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32353491" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28687413" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5673169" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Steroid resistance in bronchial asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30691708" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Three Major Efforts to Phenotype Asthma: Severe Asthma Research Program, Asthma Disease Endotyping for Personalized Therapeutics, and Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215154" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549526" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Factors associated with persistent airflow limitation in severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6784848" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Corticosteroid resistance in chronic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892860" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27773852" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14516138" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Systematic assessment of difficult-to-treat asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1671942" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cutaneous vasoconstrictor response to glucocorticoids in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8911707" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effects of prednisolone on bone turnover in patients with corticosteroid resistant asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30339770" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32173508" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Systematic Assessment of Difficult-to-Treat Asthma: Principles and Perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15265781" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31285291" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Severe T2-high asthma in the biologics era: European experts' opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32051171" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : "How can we minimise the use of regular oral corticosteroids in asthma?" Arnaud Bourdin, Ian Adcock, Patrick Berger, Philippe Bonniaud, Philippe Chanson, Cécile Chenivesse, Jacques de Blic, Antoine Deschildre, Philippe Devillier, Gilles Devouassoux, Alain Didier, Gilles Garcia, Antoine Magnan, Yan Martinat, Thierry Perez, Nicolas Roche, Camille Taillé, Pierre Val and Pascal Chanez. Eur Respir Rev 2020; 29: 190085.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27967215" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26378892" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Ethnic Variation in Response to IM Triamcinolone in Children With Severe Therapy-Resistant Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036306" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10195080" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Glucocorticoid insensitive asthma: a one year clinical follow up pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21825081" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Use of sputum eosinophil counts to guide management in children with severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937641" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32593226" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases-An EAACI position paper of the Task Force on Immunopharmacology (TIPCO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29626211" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Targeting cytokines to treat asthma and chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31078066" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pharmacological strategies to regain steroid sensitivity in severe asthma and COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32186892" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Vitamin D Metabolism Is Dysregulated in Asthma and Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21908411" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25662302" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24313760" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : How variability in clinical phenotypes should guide research into disease mechanisms in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21106547" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483109" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : T-helper type 2-driven inflammation defines major subphenotypes of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23064546" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31298922" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23471469" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32586879" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32124991" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The evolving algorithm of biological selection in severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30529449" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32667261" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
